Skip to main content
SpringerLink
Log in

Campylobacteriosis may masquerade as ibrutinib-related adverse events

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Sorin B, et al. Campylobacter infection in 4 patients treated with ibrutinib. European Journal of Clinical Microbiology and Infectious Diseases : 18 Mar 2022. Available from: URL: http://doi.org/10.1007/s10096-022-04433-4

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Campylobacteriosis may masquerade as ibrutinib-related adverse events. Reactions Weekly 1899, 7 (2022). https://doi.org/10.1007/s40278-022-11981-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-11981-x

Search

Navigation